Semaglutide gives us more than an appetite story
Human studies give us something firmer to discuss, including what happened after treatment stopped.
Start with the ingredient
Semaglutide is an altered copy of GLP-1, a hormone your gut releases in response to food. It affects appetite and helps the body handle blood sugar. That makes hunger a biology question, rather than a character test.
Wegovy and Ozempic both contain semaglutide, and both brands now have injections and tablets. Their approved uses differ by product. A familiar brand name isn't enough to identify the medicine or its purpose.
Wegovy prescribing information covers weight management and heart-risk reduction in specified groups. The injection also has accelerated approval for certain adults with MASH, a liver disease involving inflammation.
That liver use covers moderate to advanced scarring without cirrhosis, a severe stage of scarring. The approval rests on liver-sample improvements. Longer-term benefit is still being checked.
Ozempic's injection label covers type 2 diabetes and certain heart and kidney risks in people with that condition. The details matter when someone says simply that semaglutide is approved.
Weight and heart health are different findings
In the 68-week STEP 1 trial, adults had obesity, or overweight plus a weight-related condition, and no diabetes. Those taking semaglutide lost more weight on average than those taking placebo, a dummy treatment. Both groups received lifestyle support. An average from that setting isn't a forecast for you.
In SELECT, a separate heart-health trial, fewer people on semaglutide than placebo had the combined outcome of cardiovascular death, a nonfatal heart attack or a nonfatal stroke. Participants were 45 or older, had established cardiovascular disease and a BMI of at least 27, and had no diabetes. BMI relates weight to height. The finding belongs to that group.
That's useful because researchers counted health events rather than assuming a lower weight meant fewer of them. It doesn't establish the same benefit for everyone. It certainly doesn't transfer to another peptide.
What happened after stopping?
In follow-up after the weight trial, participants regained a substantial share of the weight they'd lost. This involved a subset of the original participants. The trial's lifestyle support ended when treatment stopped, too. The follow-up doesn't isolate the effect of stopping the medicine alone.
That gives a clinician and patient a reason to discuss the longer view. It doesn't decide that any particular person needs lifelong treatment. A study can sharpen that conversation without making the decision.
The warnings belong in the conversation
Nausea, vomiting, diarrhea and constipation are common side effects. The prescribing information also warns about pancreas inflammation, gallbladder problems and kidney injury linked to fluid loss. Those risks deserve more than small print.
The labels' boxed warning concerns thyroid tumors seen in rodents. Whether semaglutide causes those tumors in people is unknown. The labels rule semaglutide out with a personal or family history of medullary thyroid cancer, or the inherited condition MEN 2. This guide can't check those details against your history.
Compounded semaglutide isn't FDA-approved. Having a prescription doesn't make it the same as an approved product. The comparison keeps that difference visible.